Concerned about the ongoing market turmoil? Here are three stocks to buy and hold through tough times.
News & Analysis: Biogen
The biotech is facing several headwinds. Should investors get on board anyway?
These drug giants are gearing up for a profitable 2021.
Plus one that should be.
The drugmaker hopes its experimental new therapy could change the lives of people who struggle with Alzheimer’s disease.
This stock's value has quintupled since the last recession.
It wasn't because of revenue growth.
BIIB earnings call for the period ending June 30, 2020.
The biotech, which specializes in treating neurological diseases, may have topped estimates, but its stock barely moved.
The biotech submitted a highly anticipated regulatory filing.